Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy.
RHOJ, a small GTPase, could hold the key to the survival of tumor cells during cancer treatments. When epithelial cells transformed into mesenchymal cells, the Rho-related GTP-binding protein RhoJ regulated their resistance to chemotherapy. The scientists observed this mechanism in mouse models of skin squamous cell carcinoma, but their results could go beyond just one type of cancer. When the team started its experiments, which were published March 23, 2023, in Nature, “I had never heard about RHOJ before,” the lead author Cédric Blanpain told BioWorld. Blanpain is the director of the Laboratory of Stem Cells and Cancer at the Université Libre de Bruxelles (ULB).
Incyte Corp.’s retifanlimab-dlwr received its first regulatory nod on March 22, with the U.S. FDA granting accelerated approval for the PD-1 inhibitor to treat adults with a rare form of skin cancer, advanced Merkel cell carcinoma.
Flare Therapeutics Inc. has announced a US$123 million series B financing to support its work targeting novel transcription factors for cancer and other diseases.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have described heterocyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Ono Pharmaceutical Co. Ltd. has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a member of the cancer/testis antigens (CTAs) protein family, which is family of proteins that are mainly expressed in tumors and testicular tissue, but they display low to no expression in other normal tissues.
Oxford Drug Design Ltd. has been engaged by Phoremost Ltd. to accelerate a targeted protein degradation discovery program that seeks to identify new E3 ligase-based therapeutic strategies to treat cancer.
RSS
